Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% · 1 trial · 1 indication
Determined by corneal fluorescein staining and the effectiveness endpoint will also be evaluated by a reader using digital photography of fluorescein stained slit lamp photos and image analysis.
| Arm | Type | Description |
|---|---|---|
| Single arm active | EXPERIMENTAL | KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S), up to 6 times a day for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | DRUG | KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small. |
Inclusion Criteria: * Patients 18 years of age or older. * Patients with persistent corneal epithelial defects (PED) (Stage 1 and Stage 2 PED). * Patients with PED in one or both eyes, at least one eye meeting all study criteria. * Have PED of at least 2 weeks' duration refractory to one or more co...
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% is being developed for persistent corneal epithelial defect, an eye condition in which the cornea does not heal. It is an investigational ophthalmology product and is not approved for commercial use. Kiora Pharmaceuticals is studying it as an ocular bandage gel.
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% is developed by Kiora Pharmaceuticals, Inc., which trades under the ticker KPRX. The company is the sponsor of the clinical program for this ocular bandage gel candidate.
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% is in Phase 2 development. It is an investigational product and has not been approved by the FDA. The Phase 2 study has been completed, and no trials are currently active.
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% has been studied in one completed Phase 2 trial, NCT05436288, titled A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects. The trial enrolled 10 participants in Mexico and was uncontrolled, with no randomization or blinding.
Yes. KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% is also known as CMHA-S, which stands for crosslinked thiolated carboxymethyl hyaluronic acid. Both names refer to the same investigational ocular bandage gel being developed by Kiora Pharmaceuticals for persistent corneal epithelial defect.